IGC Pharma (NYSE American: IGC) today announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer’s murine models indicates that TGR-63 has the potential to cross the blood-brain barrier in humans. The findings build on earlier results demonstrating TGR-63’s efficacy in reducing amyloid plaque in Alzheimer’s mouse models. “These preliminary findings underscore TGR-63’s potential as a safe and effective treatment for Alzheimer’s disease,” said Ram Mukunda, CEO of IGC. “As we forge ahead with this amyloid-targeting drug, we are encouraged by its potential to offer an improved safety profile compared to currently approved treatments. This strategic approach should allow us to offer a diverse portfolio of Alzheimer’s-focused drugs that prioritize patient safety and efficacy. In addition to the focus on Alzheimer’s, we are training sophisticated AI models to analyze potential efficacy of targeting other receptors such as GLP-1, CB1, among others. We have four platforms, IGC-AD1, TGR, IGC-C, IGC-M and LMP. These platforms allow us to modify the core molecule and potentially target other receptors that could impact other diseases and conditions. We are very excited with the possibilities.”

To view the full press release, visit https://ibn.fm/A8hPT

About IGC Pharma Inc.

IGC is focused on Alzheimer’s disease, developing innovative therapies to address this devastating illness. The company’s mission is to transform the landscape of Alzheimer’s treatment with a robust pipeline of five promising drug candidates. IGC-AD1, with previously disclosed interim results, is in a Phase 2 clinical trial for agitation in dementia associated with Alzheimer’s (clinicaltrials.gov, NCT05543681). The remaining four molecules are in the pre-clinical stage of development. TGR-63 has been shown to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key hallmark of Alzheimer’s. IGC-1C targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer’s therapy. IGC-M3 aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer’s. LMP is designed to target multiple hallmarks of Alzheimer’s including plaques and tangles for a comprehensive approach to the disease. In addition to its drug development pipeline, IGC is attempting to harness the power of artificial intelligence to develop early disease detection models, optimize clinical trials, and explore new applications for its drugs.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN